Acknowledgements
Cancer
ACUTE MYELOID LEUKEMIA, CANCER
We would like to express our gratitude to Prof. Haruo Sugiyama for his suggestion of this study and data analysis. We thank Mr. Nobuhito Sanada, Ms. Akiko Kageyama, and Mr. Junji Ikeda (Otsuka Pharmaceutical Co., Ltd., Tokyo, Japan) for their helpful advice on the data of "multicenter, randomized, placebo-controlled, double-blind, comparative study (Phase II) to evaluate the efficacy and safety of OCV-501 in elderly patients with acute myeloid leukemia”, which was provided by Cancer Immunology Laboratory Co., Ltd., Osaka, Japan.